NCT01352520 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) (NCT01352520)

Trial Description
The goal of this clinical research study is to learn if brentuximab vedotin (also known as SGN-35) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.

This trial is sponsored by M.D. Anderson Cancer Center/Seattle Genetics. [1]

Study Data

  • Condition:
    • CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma
    • Primary Cutaneous Anaplastic Large Cell Lymphoma
    • Lymphomatoid Papulosis
    • Mycosis Fungoides
    • Skin Lymphoma
    • Cutaneous Lymphomas
    • Lymphoma
    • Hematologic Disorder
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 84
  • Start: June 2011
  • Estimated Primary Completion: June 2016

Study Schematic

(CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.